Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.
atezolizumab plus bevacizumab
hepatocellular carcinoma
imaging biomarker
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
14 Feb 2024
14 Feb 2024
Historique:
revised:
11
01
2024
received:
20
09
2023
accepted:
20
01
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
The IMbrave150 trial revealed that atezolizumab plus bevacizumab (AtezoBv) showed a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma (HCC). Although conversion therapy after AtezoBv has been recently reported, markers predictive of its efficacy, particularly radiological imaging markers, have not yet been identified. The present study focused on tumor morphological appearance on radiological imaging and evaluated whether it could be associated with AtezoBv efficacy. Ninety-five intrahepatic lesions in 74 patients who were given AtezoBv for advanced HCC were recruited for evaluation. The lesions were divided into two groups, simple nodular (SN group) and non-simple nodular (non-SN group), based on the gross morphology on pretreatment imaging, and retrospectively evaluated for treatment response and other relevant clinical outcomes. Assessing the size of individual tumors after treatment, waterfall plots showed that tumor shrinkage in the non-SN group including 56 lesions was higher than that in the SN group comprising 39 lesions. The ORR was significantly higher in the non-SN group (39.3% vs. 15.4%, p = 0.012). Additionally, the median time to nodular progression was longer in the non-SN group (21.0 months vs. 8.1 months, p = 0.119) compared to the SN group. Six patients with non-SN lesions underwent sequential local therapy. Atezolizumab plus bevacizumab may show increased therapeutic efficacy in patients with tumors with a higher potential for aggressive oncological behavior, such as non-SN lesions. Treatment strategies focusing on conversion therapy may be crucial in patients with non-SN lesions.
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : None
Informations de copyright
© 2024 Japan Society of Hepatology.
Références
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6. https://doi.org/10.1038/s41572-020-00240-3
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado À, et al. BCLB strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681-693.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894-1905. https://doi.org/10.1056/nejmoa1915745
Hidaka Y, Tomita M, Desaki R, Hamanoue M, Takao S, Kirishima M, et al. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report. World J Surg Oncol. 2022;20(1):228. https://doi.org/10.1186/s12957-022-02691-2
Miyata T, Sugi K, Horino T, Ono A, Tagayasu Y, Nomoto D, et al. Conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res. 2023;43(2):943-947. https://doi.org/10.21873/anticanres.16239
Kudo M. A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. Liver Cancer. 2021;10(6):539-544. https://doi.org/10.1159/000519749
Shindoh J, Kawamura Y, Kobayashi Y, Kobayashi M, Akuta N, Okubo S, et al. Prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol. 2021;28(12):7663-7672. https://doi.org/10.1245/s10434-021-09974-0
Claudia C, Jessica BF, Bertille C, Sabrina S, Lorraine B, Nathalie GC, et al. Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab. Liver Int. 2023;43(3):708-717. https://doi.org/10.1111/liv.15487
Tada T, Kumada T, Hiraokla A, Hirooka M, Kariyama K, Tani J, et al. Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis. Eur J Gastroenterol Hepatol. 2022;34(6):698-706. https://doi.org/10.1097/meg.0000000000002356
Chon YE, Cheon J, Kim H, Kang B, Ha Y, Kim DY, et al. Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment. Cancer Med. 2023;12(3):2731-2738. https://doi.org/10.1002/cam4.5161
Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y, et al. Interleukin-6 Is a circulating prognostic biomarker for hepatocellular carcinoma patients treated with combined immunotherapy. Cancers. 2022;14(4):883. https://doi.org/10.3390/cancers14040883
Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, et al. Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. Liver Cancer. 2021;10(4):380-393. https://doi.org/10.1159/000516899
Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of Hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021;10(3):181-223. https://doi.org/10.1159/000514174
Lee Y, Park H, Lee H, Cho JY, Yoon YS, Choi YR, et al. The clinicopathological and prognostic significance of the gross classification of hepatocellular carcinoma. J Pathol Transl Med. 2018;52(2):85-92. https://doi.org/10.4132/jptm.2017.11.13
Hui AM, Takayama T, Sano K, Kubota K, Akahane M, Ohmoto K, et al. Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol. 2000;33(6):975-979. https://doi.org/10.1016/s0168-8278(00)80131-2
Tada T, Kumada T, Toyoda H, Ito T, Sone Y, Okuda S, et al. Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography. J Gastroenterol. 2015;50(1):85-94. https://doi.org/10.1007/s00535-014-0947-x
Chen C, Zhao H, Fu X, Huang LS, Tang M, Yan XP, et al. Contrast-enhanced computed tomography plus gadolinium-ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging for gross classification of hepatocellular carcinoma. Oncotarget. 2017;8(18):29741-29750. https://doi.org/10.18632/oncotarget.15712
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655. https://doi.org/10.1097/00000421-198212000-00014
Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6(4):325-336. https://doi.org/10.1159/000479984
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, Staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750. https://doi.org/10.1002/hep.29913
Chou CT, Chen RC, Lin WC, Ko CJ, Chen CB, Chen YL. Prediction of microvascular invasion of hepatocellular carcinoma: preoperative CT and histopathologic correlation. AJR Am J Reoentgenol. 2014;203(3):W253-W259. https://doi.org/10.2214/ajr.13.10595
Ueno A, Masugi Y, Yamazaki K, Komuta M, Effendi K, Tanami Y, et al. OATP1B3 expression is strongly associated with Wnt/b-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61(5):1080-1087. https://doi.org/10.1016/j.jhep.2014.06.008
Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, et al. Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of anti-PD-1/PD-L1 monotherapy for unresectable hepatocellular carcinoma. Liver Cancer. 2021;10(6):615-628. https://doi.org/10.1159/000518048
Sasaki R, Nagata K, Fukushima M, Haraguchi M, Miura S, Miyaaki H, et al. Evaluating the role of hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging in predicting treatment impact of lenvatinib and atezolizumab plus bevacizumab on unresectable hepatocellular carcinoma. Cancers. 2022;14(3):827. https://doi.org/10.3390/cancers14030827
Eisenheauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1.). Eur J Cancer. 2009;45(2):228-247. https://doi.org/10.1016/j.ejca.2008.10.026
Huang C, Zhu XD, Shen YH, Wu D, ji Y, Ge NL, et al. Organ specific response to first-line lenvatinib plus anti-PD-1 antibody in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomark Res. 2021;9(1):19. https://doi.org/10.1186/s40364-021-00274-z
Kuo HY, Chiang NJ, Chuang CH, Chen CY, Wu IC, Chang TT, et al. Impact of immune checkpoint inhibitors with or without a combination of tyrosine kinase inhibitors on organ-specific efficacy and macrovascular invasion in advanced hepatocellular carcinoma. Oncol Res Treat. 2020;43(5):211-220. https://doi.org/10.1159/000505933
Sun L, Mu L, Zhou J, Tang W, Zhang L, Xie S, et al. Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71(1):25-38. https://doi.org/10.1007/s00262-021-02957-w
Kim HD, Song GW, Park S, Jung MK, Kim MH, Kang HJ, et al. Association between expression level of PD1 by tumor-infiltrating CD8+ T cells and features of hepatocellular carcinoma. Gastroenterology. 2018;155(6):1936-1950. https://doi.org/10.1053/j.gastro.2018.08.030
Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15(10):599-616. https://doi.org/10.1038/s41571-018-0073-4
Kuwano A, Yada M, Narutomi F, Nagasawa S, Tanaka K, Kurosaka K, et al. Therapeutic efficacy of atezolizumab plus bevacizumab for hepatocellular carcinoma with WNT/β-catenin signal activation. Oncol Lett. 2022;24(1):216. https://doi.org/10.3892/ol.2022.13337